NDAORALCAPSULE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRINCIPEN '250' is an oral ampicillin capsule formulation developed by Bristol Myers Squibb for pre-launch market entry. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, used to treat a broad spectrum of bacterial infections.
Pre-Launch
Pre-launch stage indicates emerging commercial structure with opportunities in launch team building and market entry planning, though current team size is undefined.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRINCIPEN '250' represents a pre-launch career opportunity focused on market entry execution and regulatory clearance. Limited current linked job openings suggest this is an emerging initiative with growth potential post-approval.
Regulatory Affairs SpecialistBrand Manager
Worked on PRINCIPEN '250' at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.